Boston-based Indigo announced Tuesday the first closing of $156 million in its Series D financing, doubling the company’s total capital...

Proceeds Will Support Further Development of Proprietary Tumor Antigen Identification Platform and Advancement of Pipeline of...

July 26, 2017 at 7:30 PM EDT WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA)...

July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer,...

South San Francisco, Calif. – June 20, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and...

SAN DIEGO, June 20, 2017 /PRNewswire/ -- eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply...

BLACKTHORN’S BTRX-246040 NOCICEPTIN PROGRAM IS FIRST MOLECULE AND CLINICAL PROGRAM TO INCORPORATE MINDSTRONG HEALTH’S PATENTED TECHNOLOGY...

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and...

Indigo™ Cotton demonstrated an average yield improvement of 11% in the target environment of West Texas Farmers experienced productivity...